Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 14
Minocycline as adjunct therapy for a male patient with deficit schizophrenia
Authors Chen X, Xiong Z, Li Z, Yang Y, Zheng Z, Li Y, Xie Y, Li Z
Received 10 July 2018
Accepted for publication 16 September 2018
Published 12 October 2018 Volume 2018:14 Pages 2697—2701
DOI https://doi.org/10.2147/NDT.S179658
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 4
Editor who approved publication: Professor Yuping Ning
Xiaohua Chen,1,* Zhenzhen Xiong,2,* Zhixiong Li,3 Yali Yang,4 Zhanying Zheng,5 Yonghong Li,6 Yan Xie,6 Zhe Li7,8
1Department of Central Transportation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China; 2School of Nursing, Chengdu Medical College, Chengdu, Sichuan 610083, China; 3The Third Department of Clinical Psychology, Karamay Municipal People’s Hospital, Karamay, Xinjiang 830054, China; 4The Second Department of Clinical Psychology, Karamay Municipal People’s Hospital, Karamay, Xinjiang 830054, China; 5The First Department of Clinical Psychology, Karamay Municipal People’s Hospital, Karamay, Xinjiang 830054, China; 6The Sleep Medicine Department, Karamay Municipal People’s Hospital, Karamay, Xinjiang 830054, China; 7Mental Health Center and Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China; 8The Mental Rehabilitation Center, Karamay Municipal People’s Hospital, Karamay, Xinjiang 830054, China
*These authors contributed equally to this work
Abstract: The pathophysiology of schizophrenia may involve increased production of inflammatory cytokines by activated microglia. Minocycline can inhibit activated microglia and may improve secondary negative symptoms and/or cognitive functions when used as adjuvant to antipsychotics. Effects on minocycline on primary and enduring negative symptoms in deficit schizophrenia (DS) are unknown. We present a male patient with a 3-year history of DS. He was treated for 12 weeks with risperidone at a maximal dose of 6 mg per day, then for 10 weeks with olanzapine at 20 mg per day. Symptoms did not improve, and body mass index increased from 20.41 to 22.84 kg/m2. Serum levels of several inflammatory cytokines were elevated, so we prescribed minocycline as adjunct to aripiprazole for 12 weeks. Negative symptoms and cognitive impairment improved, and serum levels of inflammatory cytokines decreased. Our case suggests that clinicians may consider minocycline as adjunct therapy to antipsychotics in patients with DS with elevated serum levels of inflammatory cytokines. This highlights the need for further research into possible relationships of minocycline with negative symptoms and cognitive function in patients with DS.
Keywords: minocycline, adjunct therapy, deficit schizophrenia
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.